Baidu
map

HBx与AIB1协同加速肝细胞癌进程

2012-04-10 庞琳娜 科学网

文献标题:Hepatitis B virus X protein stabilizes AIB1 protein and cooperates with it to promote human hepatocellular carcinoma cell invasiveness 文献来源:Hepatology. 2012 Apr 2. 期刊影响因子:10.885   

文献标题:Hepatitis B virus X protein stabilizes AIB1 protein and cooperates with it to promote human hepatocellular carcinoma cell invasiveness
文献来源:Hepatology. 2012 Apr 2.
期刊影响因子:10.885

       厦门大学生命科学学院的研究人员在肝癌研究方面取得新进展,证实了研究证实乙肝病毒X蛋白(HBx)与AIB1蛋白具有协同作用,两者共同作用可提高人类肝细胞癌(HCC)细胞的侵袭性,加速HBV相关性HCC的进程。相关研究成果于4月2日在线发表于国际著名期刊《Hepatology》上。
  
       人类肝细胞癌(HCC)是最常见的肝脏肿瘤,在世界范围内肿瘤相关性死亡因素中排名第三,全球每年有超过50万新患者,中国新病例占了全球所有肝癌病例的一半以上(55%)。目前临床上最主要治疗肝癌的方法是手术切除和肝脏移植,经肝动脉栓塞的化疗法则作为第二线治疗。但是由于肝癌复发率高、且抗化疗药性强,整体治疗效果并不理想。多年来科学家们一直致力于解析肝癌发生发展机制以寻找有效的预后判断标志物与治疗靶标。
 
       乙型肝炎病毒(HBV)慢性感染与人类肝细胞癌的发展密切相关,而乙肝病毒X蛋白(HBx)在肝细胞癌的进展中起着关键的作用。AIB1蛋白在68%的人肝癌标本中过度表达并可通过增强细胞增殖和侵袭能力而促进肝癌的进展。由于HBx和AIB1在肝癌进展中发挥着重要的作用,研究人员希望了解它们是否协同促进了肝癌的发展。
 
       在这篇文章中,研究人员发现与HBx阴性肝癌组织相比,HBx阳性肝癌组织中AIB1蛋白的水平较高,并且HBx蛋白水平和AIB1蛋白水平呈正相关。在不影响其mRNA水平的情况下,HBx可通过延长AIB1蛋白的半衰期来使AIB1的蛋白水平增加。HBx蛋白通过与AIB1的结合来阻止E3 泛素连接酶Fbw7a和AIB1的结合,进而抑制Fbw7a对AIB1的泛素化降解。此外,HBx和AIB1可募集到MMP-9 启动子上协同促进MMP-9启动子的活性,进而增强MMP-9在HepG2 细胞中的表达而促进细胞的侵袭能力。
 
       该研究表明HBx可稳定AIB1蛋白并与它协同促进肝癌细胞的侵袭,说明HBx和AIB1之间的相互作用在乙肝病毒相关的肝癌进展中起着重要的作用。

       文章是由厦门大学生命科学学院俞春东教授的课题组完成的,该课题组主要从事核受体及其共激活子在肝脏代谢及肝脏疾病中的作用,及核受体及其共激活子在炎症反应及自身免疫疾病中的作用等研究。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1863181, encodeId=ae1d1863181f9, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Mar 16 03:37:00 CST 2013, time=2013-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997189, encodeId=e13c199e1897b, content=<a href='/topic/show?id=74818543ea' target=_blank style='color:#2F92EE;'>#HBx#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8543, encryptionId=74818543ea, topicName=HBx)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Sun Jan 06 03:37:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779624, encodeId=5e101e79624d1, content=<a href='/topic/show?id=3e292162e4' target=_blank style='color:#2F92EE;'>#AIB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2162, encryptionId=3e292162e4, topicName=AIB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue May 01 11:37:00 CST 2012, time=2012-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978310, encodeId=363a19e831045, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Wed Jan 09 18:37:00 CST 2013, time=2013-01-09, status=1, ipAttribution=)]
    2013-03-16 xjy02
  2. [GetPortalCommentsPageByObjectIdResponse(id=1863181, encodeId=ae1d1863181f9, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Mar 16 03:37:00 CST 2013, time=2013-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997189, encodeId=e13c199e1897b, content=<a href='/topic/show?id=74818543ea' target=_blank style='color:#2F92EE;'>#HBx#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8543, encryptionId=74818543ea, topicName=HBx)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Sun Jan 06 03:37:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779624, encodeId=5e101e79624d1, content=<a href='/topic/show?id=3e292162e4' target=_blank style='color:#2F92EE;'>#AIB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2162, encryptionId=3e292162e4, topicName=AIB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue May 01 11:37:00 CST 2012, time=2012-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978310, encodeId=363a19e831045, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Wed Jan 09 18:37:00 CST 2013, time=2013-01-09, status=1, ipAttribution=)]
    2013-01-06 nian.wang1982
  3. [GetPortalCommentsPageByObjectIdResponse(id=1863181, encodeId=ae1d1863181f9, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Mar 16 03:37:00 CST 2013, time=2013-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997189, encodeId=e13c199e1897b, content=<a href='/topic/show?id=74818543ea' target=_blank style='color:#2F92EE;'>#HBx#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8543, encryptionId=74818543ea, topicName=HBx)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Sun Jan 06 03:37:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779624, encodeId=5e101e79624d1, content=<a href='/topic/show?id=3e292162e4' target=_blank style='color:#2F92EE;'>#AIB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2162, encryptionId=3e292162e4, topicName=AIB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue May 01 11:37:00 CST 2012, time=2012-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978310, encodeId=363a19e831045, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Wed Jan 09 18:37:00 CST 2013, time=2013-01-09, status=1, ipAttribution=)]
    2012-05-01 millore
  4. [GetPortalCommentsPageByObjectIdResponse(id=1863181, encodeId=ae1d1863181f9, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Sat Mar 16 03:37:00 CST 2013, time=2013-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1997189, encodeId=e13c199e1897b, content=<a href='/topic/show?id=74818543ea' target=_blank style='color:#2F92EE;'>#HBx#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8543, encryptionId=74818543ea, topicName=HBx)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Sun Jan 06 03:37:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779624, encodeId=5e101e79624d1, content=<a href='/topic/show?id=3e292162e4' target=_blank style='color:#2F92EE;'>#AIB1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2162, encryptionId=3e292162e4, topicName=AIB1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue May 01 11:37:00 CST 2012, time=2012-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978310, encodeId=363a19e831045, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Wed Jan 09 18:37:00 CST 2013, time=2013-01-09, status=1, ipAttribution=)]

相关资讯

Hepatology:肝细胞癌(HCC)1~2cm不确定结节是否活检?

 加拿大一项研究报告,肝脏1~2cm不确定结节的恶性率较低,对所有这些结节进行活检会导致许多阴性结果,将活检限定于高动脉血供或者同时存在典型HCC的结节则可以检出多数HCC,并且使活检量大大减少。论文发表于《肝脏病学》[Hepatology 2011,54(6):2048]。   该研究连续纳入80例患者共计93个不确定的结节,其中85个结节获得最终诊断,包括13个恶性结节和72个良性结节。通

原发性肝细胞癌普通外科临床路径(2011年版)

 近日,卫生部印发了原发性肝细胞癌普通外科临床路径(2011年版)。   原发性肝细胞癌临床路径   (2011年版)      一、原发性肝细胞癌临床路径标准住院流程   (一)适用对象。   第一诊断为原发性肝细胞癌(ICD-10:C22.0)   行规则性肝切除或非规则性肝切除术(ICD-9-CM-3:50.22/50.3)。   (二)诊断依据。   根据《临床诊疗指南

人类白细胞抗原G蛋白表达是肝细胞癌治愈性切除后的一种不良预后因子

MedSci简评:这篇文章中上海中山医院肝癌研究所的文章,文章并不复杂,主要研究HLA-G对肝癌预后的判断。特色有:(1)选择的是肝癌治愈性切除后的样本;(2)采用了组织芯片技术;(3)样本量较大;(4)研究切入当前的热点如Treg作用。 Human leukocyte antigen-G protein expression is an unfavorable prognostic predi

综合评分可用于对晚期肝细胞癌患者进行分层

  《肿瘤学》(Oncology)杂志近期发表的一项研究结果提示,意大利肝癌计划评分或Okuda评分结合体能状态(PS)可用于对接受索拉菲尼治疗的晚期肝细胞癌(HCC)患者进行分层。   该研究从1个中心收集了201例接受索拉非尼治疗的转移性HCC患者的数据。结果显示,慢性乙型肝炎是肝癌的最主要病因(84%)。 在162例可评估的患者中,4例得到部分缓解。中位随访15.7个月时,中位无

Baidu
map
Baidu
map
Baidu
map